We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.07B
AUM Growth
+$212M
Cap. Flow
+$369M
Cap. Flow %
5.23%
Top 10 Hldgs %
69.18%
Holding
43
New
7
Increased
10
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$109M
2
ALKS icon
Alkermes
ALKS
+$70.4M
3
VERA icon
Vera Therapeutics
VERA
+$57.6M
4
ARWR icon
Arrowhead Research
ARWR
+$45.8M
5
MRUS
Merus
MRUS
+$37M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.5M
2
UTHR icon
United Therapeutics
UTHR
+$36.2M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$27.6M
4
DYN icon
Dyne Therapeutics
DYN
+$23.3M
5
KURA icon
Kura Oncology
KURA
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
26
uniQure
QURE
$3.15B
$38.4M 0.54%
+2,175,000
New +$18.8M
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.55B
$34.9M 0.49%
830,000
– –
TSHA icon
28
Taysha Gene Therapies
TSHA
$1.82B
$34.6M 0.49%
19,999,999
+1,349,999
+7% +$2.8M
ETNB
29
DELISTED
89bio
ETNB
$32.1M 0.45%
+4,100,000
New +$33.8M
GLUE icon
30
Monte Rosa Therapeutics
GLUE
$1.33B
$30.2M 0.43%
4,345,000
-1,445,236
-25% -$10.8M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.76B
$30.1M 0.43%
2,275,000
-1,613,437
-41% -$27.6M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$2.77B
$25.9M 0.37%
3,500,000
-740,000
-17% -$6.86M
SEPN
33
Septerna Inc
SEPN
$1.78B
$25.4M 0.36%
+1,110,000
New +$26.2M
AUTL
34
Autolus Therapeutics
AUTL
$532M
$23.3M 0.33%
9,910,642
-2,435,036
-20% -$8.23M
CGON icon
35
CG Oncology
CGON
$6.6B
$20.1M 0.28%
700,000
– –
KURA icon
36
Kura Oncology
KURA
$824M
$19.6M 0.28%
2,250,000
-1,291,505
-36% -$18.6M
RCKT icon
37
Rocket Pharmaceuticals
RCKT
$387M
$15.1M 0.21%
+1,200,000
New +$18.1M
OLMA icon
38
Olema Pharmaceuticals
OLMA
$1.03B
$9.63M 0.14%
+1,651,982
New +$16.5M
WHWK
39
Whitehawk Therapeutics
WHWK
$232M
$8.99M 0.13%
2,849,402
– –
DYN icon
40
Dyne Therapeutics
DYN
$4.83B
– –
-650,000
Closed -$23.3M
INSM icon
41
PUT
Insmed
INSM
$28.9B
– –
-50,000
Closed -$125K
NGNE icon
42
Neurogene
NGNE
$710M
– –
-22,029
Closed -$924K
SYRE icon
43
Spyre Therapeutics
SYRE
$9.12B
– –
-598,600
Closed -$17.6M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Avoro Capital Advisors held 43 positions worth $7.07B, up 3.1% from $6.86B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors deployed $369M of net new capital in Q4 2024, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was Blueprint Medicines: 1,185,000 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $38.5M trimmed.

  • Avoro Capital Advisors's largest Q4 2024 buy was Blueprint Medicines: 1,185,000 shares worth $103M.
  • Avoro Capital Advisors added most to Vera Therapeutics in Q4 2024, an estimated $57.6M increase.
  • Avoro Capital Advisors's biggest Q4 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $38.5M.
  • Avoro Capital Advisors fully exited Dyne Therapeutics in Q4 2024, selling an estimated $23.3M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $7.07B portfolio in Q4 2024.
  • Avoro Capital Advisors opened 7 new positions and closed 4 in Q4 2024.
  • Avoro Capital Advisors's portfolio value rose 3.1% quarter-over-quarter to $7.07B.

Based on Avoro Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.